Search | Clinical Trials Finder

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions: Placebo, Linaclotide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,722 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 52
States / cities: Huntsville, Alabama • North Little Rock, Arkansas • Phoenix, Arkansas + 49 more

Conditions: Metabolic Syndrome X
Interventions: Astaxanthin, Placebo; Dietary Supplement · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Rheumatoid Arthritis
Interventions: Leflunomide, Methotrexate, Ocrelizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 836 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 144
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more

Conditions: Neurodermatitis
Interventions: Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more

Conditions: Mantle-Cell Lymphoma
Interventions: Ibrutinib, Venetoclax, Placebo Oral tablet to match Venetoclax; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 14
States / cities: Tucson, Arizona • Duarte, California • Los Angeles, California + 10 more

Conditions: Irritable Bowel Syndrome
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Rochester, Minnesota • La Crosse, Wisconsin

Conditions: Cystitis, Interstitial, Painful Bladder Syndrome
Interventions: LiRIS®, LiRIS Placebo; Combination Product
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 31
States / cities: Mobile, Alabama • Escondido, California • Los Angeles, California + 27 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: JNJ-53718678, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 28 Days to 3 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Madera, California • Ventura, California • Aurora, Colorado + 11 more

Conditions: Alzheimer's Disease
Interventions: E2212, placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • Santa Barbara, California • Gainesville, Florida + 8 more

Conditions: Major Depressive Disorder
Interventions: Lisdexamfetamine Dimesylate (Vyvanse), Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Proteinuric Kidney Disease
Interventions: VX-147, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 10 Years to 65 Years
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 227
States / cities: Alabaster, Alabama • Birmingham, Alabama • Fairhope, Alabama + 145 more

Conditions: Healthy Participants
Interventions: AZD8965, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 147 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Cardiovascular Disease, Oxidative Stress
Interventions: Chokeberry Extract, Placebo capsule, Chokeberry extract capsule, acute; Dietary Supplement
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Pain, Postoperative
Interventions: Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 440 mg (BAYH6689), DPH 50 mg; Drug
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 45 Years
Enrollment: 712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Austin, Texas • Salt Lake City, Utah

Conditions: Primary IgA Nephropathy
Interventions: Sefaxersen (RO7434656), Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 20
States / cities: Birmingham, Alabama • Glendale, California • Los Angeles, California + 15 more

Conditions: Hyperlipidemia
Interventions: ARI-3037MO; Drug
Lead sponsor: Arisaph Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 19
States / cities: Chino, California • Fort Lauderdale, Florida • Jacksonvile, Florida + 12 more

Conditions: Nocturia
Interventions: Desmopressin, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 10
States / cities: Aventura, Florida • DeLand, Florida • Peoria, Illinois + 6 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 994 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 42
States / cities: Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more

Conditions: Ovarian Cancer
Interventions: Pazopanib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 35
States / cities: Anaheim, California • Baldwin Park, California • Bellflower, California + 27 more

Conditions: Spinocerebellar Ataxia Type 3
Interventions: BIIB132, BIIB132-Matching Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Gainesville, Florida + 7 more

Conditions: QTc Interval, Pharmacokinetics
Interventions: Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose; Drug
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Duchenne Muscular Dystrophy
Interventions: delandistrogene moxeparvovec, placebo; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: Male only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 14
States / cities: Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 11 more

Conditions: Covid19
Interventions: Niclosamide, Placebo; Drug
Lead sponsor: Entero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • DeLand, Florida • Hialeah, Florida + 7 more

Search by objective public record fields.

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

Study of Chokeberry to Reduce Cardiovascular Disease Risk in Former Smokers

Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia

Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3

An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection